<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc041202.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2004

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 2 December,2004  By /s/Ronald Lea Erratt Company Secretary

2 December, 2004

The Manager
Company Announcements Platform
Australian Stock Exchange
Dear Sir

Letter to Shareholders of Glycotex, Inc.

Attached is a copy of a letter sent recently to the shareholders of
Glycotex, Inc.,
a subsidiary Of Novogen Limited.

Yours faithfully

Ron Erratt
Company Secretary

Glycotex Inc.
C\- Novogen Limited, 140 Wicks Road,
North Ryde, NSW, 2113, Australia

1 December, 2004

Dear Shareholder
Clinical trial update.

This report is to provide a short update on the
current Phase II trial in progress.
We have had great co-operation from Dr Rodney Lane at
Royal North Shore Hospital, and more recently from the
Austin Hospital in Melbourne.  Between them, they should
have all 60 patients enrolled imminently, meaning that
we should have the final data by the end of March 2005
assuming that the report is prepared promptly.  Patient
enrolment has taken us longer than we expected because
the treatment of trophic ulcers is not as centralised
or coordinated in hospitals in Australia as are other
disease conditions.

The clinical trial is double-blinded, which means that
neither doctors nor patients know whether they are
receiving placebo or active.  To break the code at
this stage and have the outcome known would jeopardise
the integrity of the trial and put the outcome at risk.
However, as an interim analysis was allowed by the
protocol to ensure that we were on track to achieve a
definable outcome with the planned 60 patients, an
interim analysis was conducted recently by Dr Graham Kelly.
It is pleasing to report that we are on track to
achieve an outcome, however I hasten to add that this
could mean one of two things: either, (a) that we are on
track to achieve a statistically significant outcome,
or (b) that we are on track to confirm that we will
never achieve that outcome.  Although still considered
that 60 patients should be enough for a definitive
result either way, it is of course not open to us to
reveal whether any bias towards (a) or (b) was seen
in the interim review.

If we were to achieve a clinically beneficial outcome
in the treatment of trophic ulcers, Glucoprime would
be the first test product to achieve that result of
complete healing.  As reported at the Novogen Limited
Annual General Meeting, and as shown in the presentation
on the Novogen web site, a number of patients in the
current trial have experienced complete healing responses.
Although it is not known at this stage whether they are
in the active or placebo groups, we find this result very
interesting.

The intellectual property contained in the patent
licensed by Glycotex and now granted in a number of
countries including the USA, is based on Glucoprime
and its analogues promoting healing across a wide
variety of therapeutic uses.  There are a number of
options open to us once we complete the current
Phase II trial and assuming that it has a positive
outcome. While trophic ulcers represent the most
challenging end of the spectrum, because they involve
wounds that are dysfunctional, there are many other
clinical opportunities in areas which are not
dysfunctional and where Glucoprime may be expected
to provide a benefit.

One of our options could be to seek registration of
the product in certain territories on the basis of
the Phase II data.  Some territories, such as the
USA and Europe, would need Phase III trial data, and
that is something that will be considered.  Another
option is to pursue the more general application of
promotion of wound healing in general surgical wounds.
In animal studies, Glucoprime has reduced by 40%
the time to complete healing in surgical wounds,
pointing to a large and exciting potential application
in general surgery.  Other more interesting applications
include promotion of healing in tissues such as tendons,
ligaments and bones, which are also typically slow to heal.

Glycotex has patent coverage over these other uses.
Pending confirmation that the outcome of the current
clinical trial is positive, active and exciting times
await us, and, again, I thank you for your support.

Regards

Christopher Naughton
CEO
Glycotex, Inc.




Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088

</TEXT>
</DOCUMENT>
